<DOC>
	<DOCNO>NCT02343783</DOCNO>
	<brief_summary>The purpose study characterize cell ( basic building block live thing ) population inflammatory ( pain swell ) mediator response suction skin blister fluid allergic skin reaction ( ASR ) [ rash ] induction D. Pteronyssinus [ house dust mite ( HDM ) ] , Alternaria alternata , Aspergillus fumigatus allergens participant atopic dermatitis ( AD ) [ Skin rash , Eczema ] allergic asthma ( AA ) [ breathe disorder wheeze difficulty breathe ] .</brief_summary>
	<brief_title>A Study Evaluate Use Induced Skin Blisters Adult Participants With Atopic Dermatitis , Allergic Asthma Atopic Healthy Participants</brief_title>
	<detailed_description>This interventional ( treatment give course research study ) multicenter ( one hospital medical school team work medical research study ) study . The study consist 3 Phases : Screening Phase ( Up 4 week ) , Data Collection Phase ( 9 day ) , Follow-up Phase ( 7 day ) . The maximum study duration participant exceed 43 day . Primarily , cell population inflammatory mediator response suction skin blister fluid allergic skin reaction ( ASR ) assess . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Blister</mesh_term>
	<criteria>Participant must sign informed consent document prior study related procedure indicate understand purpose procedure require study willing participate study Participant must willing/able adhere study visit schedule requirement , prohibition restriction specify protocol * For participant Asthma : Participant must physician documented diagnosis asthma least 12 month Screening Participant must Asthma Control Questionnaire 6 ( ACQ6 ) less ( &lt; ) 1.5 Screening * For participant Atopic Dermatitis : Participant must physician documented diagnosis atopic dermatitis least 12 month Screening base UK refinement Hanifin Rajka 's diagnostic criterion Participant must atopic dermatitis Investigators Global Assessment ( IGA ) score 2 4 Screening Participant take prohibit restricted medication note Prestudy Concomitant Therapy Participant receive investigational drug ( include investigational vaccine ) use invasive investigational medical device within 6 week 5 halflives ( whichever longer ) Screening visit * For participant Asthma : Participant history lifethreatening asthma , define history respiratory arrest require intubation asthma Participant admit hospital asthma 1 year Screening * For participant Atopic Dermatitis : Participant evidence skin condition would interfere assessment Atopic Dermatitis ( AD ) Participant active AD related infection active AD infection within 2 week Screening ( participant evidence colonization skin swab test infection allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Asthma</keyword>
	<keyword>Healthy</keyword>
	<keyword>Skin Blisters</keyword>
	<keyword>Adult Participants</keyword>
</DOC>